Mantle cell lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 20
• BTK 17
• CD20 8
• TP53 2
• BCL-2 5
• PI3K 0
• CD22 3
• MYC 0
• PD-1 2
• CXCR4 0
• EGFR 0
• PD-L1 1
• PRMT5 0
• ALK 0
• CD47 0
• JAK 0
• STAT3 0
• AKT 0
• ATM 0
• BRCA1 1
• BRCA2 1
• BRD4 0
• CCR5 0
• CD40 0
• FLT3 0
• GPX4 0
• HDAC 0
• HSP90 0
• KMT2A 0
• MET 0
• mTOR 0

24 of 30+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIGMS · F32

  Elucidating the role of N-glycanase in glycoprotein activation, trafficking, and degradation

  Stanford University· Stanford, United States· US$76,780 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · K99

  Mechanisms of enhancer regulation by EBF1 in mantle cell lymphoma.

  University of Pennsylvania· Philadelphia, United States· US$147,874 awarded in fiscal year 2026· until Jul 2028

• NIH NCI · K08

  Unraveling the Mechanisms of Cyclin D1-Induced Replication Stress and DNA Damage Repair Dependencies in Mantle Cell Lymphoma: A Path to Novel Therapeutic Strategies for High-Risk Disease

  Mayo Clinic Rochester· Rochester, United States· US$324,272 awarded in fiscal year 2026· until Jul 2031

• NIH NCI · R21

  The role of ERBB signaling in ibrutinib-resistant mantle cell lymphoma

  Beckman Research Institute/City of Hope· Duarte, United States· US$457,683 awarded in fiscal year 2026· until May 2028

• NIH NCI · R50

  Efforts to Discover Novel Therapies and Reduce Treatment Toxicities for Lymphoma and Chronic Lymphocytic Leukemia Patients Through Collaboration and the NCTN

  Utah State Higher Education System--University of Utah· Salt Lake City, United States· US$935,075 awarded in fiscal year 2025· until Aug 2029

5 of 24 running projects, newest first. Listed amounts together: US$20.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

  NCT05471843· BeOne Medicines· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• Gene Expression Profiling 6
• Proteomics 1
• Flow Cytometry 6
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 7
• Magnetic Resonance Imaging 1
• Machine Learning 2
• Deep Learning 1
• Cohort Studies 2

• Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma-Where we are and where we're headed.

  Semin Hematol, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.